The EMPA-KIDNEY trial has demonstrated that empagliflozin reduces the risk of kidney disease progression or death from cardiovascular disease by 28% in people with chronic kidney disease.
Oxford Population Health are a world-leading research institute that investigates the causes and prevention of diseases.
Read more: [ Ссылка ]
![](https://s2.save4k.ru/pic/ah3SmC2kvc0/maxresdefault.jpg)